

Personal Information

Email: fatihkus@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/fatihkus>

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study**
Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., Şakalar T., Celayir Ö. M., KAYIKÇIOĞLU E., Aslan F., et al.
International Journal of Clinical Oncology, vol.29, no.3, pp.258-265, 2024 (SCI-Expanded)
- II. **Sirolimus experience in adult patients with vascular malformations**
AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., Chalabiyev E., TÜRKER F. A., DİZDAR Ö., YALÇIN Ş., et al.
Vascular, 2024 (SCI-Expanded)
- III. **Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort**
AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., Chalabiyev E., KUŞ F., YALÇIN Ş., AKSOY S.
Medicine (United States), vol.102, no.18, 2023 (SCI-Expanded)
- IV. **KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer**
KUŞ F., Guven D. C., YILDIRIM H. Ç., Chalabiyev E., AKYILDIZ A., Tatar O. D., ŞAHİN Y., Ileri S., Karaca E., KERTMEN N., et al.
Biomarkers in Medicine, vol.17, no.7, pp.379-389, 2023 (SCI-Expanded)
- V. **Knowledge and Protective Behaviors of Teachers on Skin Cancer: A Cross-Sectional Survey Study from Turkey**
Kus C., Kus M. M., Keten H. S., Ucer H., Guvenc N., KUŞ F., YILDIRIM H. Ç., Akbayram H. T.
Children, vol.10, no.2, 2023 (SCI-Expanded)
- VI. **Emerging treatment strategies in hepatobiliary cancer**
GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., AKYILDIZ A., AKTAŞ B. Y., YALÇIN Ş., DİZDAR Ö.
Expert Review of Anticancer Therapy, vol.23, no.3, pp.243-256, 2023 (SCI-Expanded)
- VII. **Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment**
Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., AKSOY S.
Expert Review of Anticancer Therapy, vol.23, no.10, pp.1049-1059, 2023 (SCI-Expanded)

Articles Published in Other Journals

- I. **Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab**
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., AKSOY S., ERMAN M., YALÇIN Ş., Kilickap S.

Journal of Immunotherapy and Precision Oncology, vol.6, no.4, pp.170-176, 2023 (Scopus)

II. **Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer**

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., AKYILDIZ A., YILMAZ F., YAŞAR S., Evlendi Y., et al.

Journal of Oncological Science, vol.9, no.1, pp.33-37, 2023 (Scopus)

III. **Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy**

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., KUŞ F., AKYILDIZ A., GÜRBÜZ S. Ç., Sayin H., et al.

Journal of Oncological Science, vol.8, no.3, pp.143-147, 2022 (Scopus)

Metrics

Publication: 10